Document is current
Any future updates will be listed below
-
Authors
Kaveh, Aryan https://orcid.org/0000-0003-4097-1939
Salazar-Martin, Antonio G. https://orcid.org/0000-0002-9769-8788
Dai, Wei https://orcid.org/0000-0001-6069-9616
Kithcart, Aaron P.
Pan, Emily https://orcid.org/0000-0001-9624-6539
KC, Ashmita https://orcid.org/0000-0002-8831-5124
Reinoso, Tyler R.
Vetrano-Olsen, Franki
Saha, Kusumika
Beerens, Manu https://orcid.org/0000-0002-7398-7761
Libby, Peter https://orcid.org/0000-0002-1502-502X
Edelman, Elazer R. https://orcid.org/0000-0002-7832-7156
MacRae, Calum A. https://orcid.org/0000-0001-5181-2664
- License Information
-
More Information
Article History
Received: 3 February 2025
Accepted: 23 April 2026
First Online: 21 May 2026
Competing interests
: C.A.M. has received consulting income from Astellas, Novo Nordisk, Bayer and Pfizer for work in areas related to this work. P.L. is a member of the scientific advisory board for Amgen, Caristo Diagnostics, CSL Behring, Elucid Bioimaging, Kancera, Kowa Pharmaceuticals, Olatec Therapeutics, Novartis, PlaqueTec, Polygon Therapeutics, TenSixteen Bio, Soley Thereapeutics, and XBiotech, Inc. PL has a financial interest in Xbiotech, TenSixteen Bio and in Soley Therapeutics. The remaining authors declare no competing interests.
